Rate-controlled rectal drug delivery in man with a hydrogel preparation

Cylindrical hydrogels of hydroxyethyl methacrylate (HEMA) and ethylene glycol dimethacrylate (EGDMA) as crosslinking agent were prepared by radical polymerization at 70°C. After washing they were soaked in an aqueous drug solution of antipyrine or theophylline. The in vitro drug release experiments were performed in 100 ml isotonic glucose at 37°C. Rectal administration of a hydrogel preparation containing antipyrine was performed in two subjects for 72 h. With a theophylline-containing hydrogel preparation rectal drug administration was performed in six volunteers for 24 h. Plasma and saliva samples were taken regularly and the in vivo drug release was determined by means of a deconuolution procedure. In vitro 1.12g antipyrine had been released according to a matrix-type profile for 72 h, whereas it was calculated that this was 1.13 and 1.09 g in vivo in the two subjects. The release profile in vivo was very similar to that in vitro. The theophylline hydrogel preparation released in vitro a total of 288 ± 6 mg of drug in 24 h and in vivo this amount was calculated to be 288 ± 11 mg (mean ± s.d.). Near-constant plasma theophylline concentrations were obtained after administering the hydrogel preparation. In all six subjects the cumulative drug profile was in almost perfect agreement with that observed in vitro. Hydrogels offer interesting perspectives as rate-controlled rectal drug delivery systems because of the predictable release profile in vivo on the basis of observations in a simple in vitro model

New limits on a cosmological constant from statistics of gravitational lensing

We present new limits on cosmological parameters from the statistics of gravitational lensing, based on the recently revised knowledge of the luminosity function and internal dynamics of E/S0 galaxies that are essential in lensing high-redshift QSOs. We find that the lens models using updated Schechter parameters for such galaxies, derived from the recent redshift surveys combined with morphological classification, are found to give smaller lensing probabilities than earlier calculated. Inconsistent adoption of these parameters from a mixture of various galaxy surveys gives rise to systematic biases in the results. We also show that less compact dwarf-type galaxies which largely dominate the faint part of the Schechter-form luminosity function contribute little to lensing probabilities, so that earlier lens models overestimate incidents of small separation lenses. Applications of the lens models to the existing lens surveys indicate that reproduction of both the lensing probability of optical sources and the image separations of optical and radio lenses is significantly improved in the revised lens models. The likelihood analyses allow us to conclude that a flat universe with Omega=0.3(+0.2-0.1) and Omega+Lambda=1 is most preferable, and a matter-dominated flat universe with Lambda=0 is ruled out at 98 % confidence level. These new limits are unaffected by inclusion of uncertainties in the lens properties.Comment: 30 pages, 9 ps figures, AASTeX, ApJ in pres

Enhancement of drug oxidation and conjugation by carcinogens in different rat tissues

OBJECTIVE After endoscopic third ventriculostomy (ETV), some patients develop recurrent symptoms of hydrocephalus. The optimal treatment for these patients is not clear: repeat ETV (re-ETV) or CSF shunting. The goals of the study were to assess the effectiveness of re-ETV relative to initial ETV in pediatric patients and validate the ETV success score (ETVSS) for re-ETV. METHODS Retrospective data of 624 ETV and 93 re-ETV procedures were collected from 6 neurosurgical centers in the Netherlands (1998-2015). Multivariable Cox proportional hazards modeling was used to provide an adjusted estimate of the hazard ratio for re-ETV failure relative to ETV failure. The correlation coefficient between ETVSS and the chance of re-ETV success was calculated using Kendall's tau coefficient. Model discrimination was quantified using the c-statistic. The effects of intraoperative findings and management on re-ETV success were also analyzed. RESULTS The hazard ratio for re-ETV failure relative to ETV failure was 1.23 (95% CI 0.90-1.69; p = 0.20). At 6 months, the success rates for both ETV and re-ETV were 68%. ETVSS was significantly related to the chances of re-ETV success (tau = 0.37; 95% bias corrected and accelerated CI 0.21-0.52; p < 0.001). The c-statistic was 0.74 (95% CI 0.64-0.85). The presence of prepontine arachnoid membranes and use of an external ventricular drain (EVD) were negatively associated with treatment success, with ORs of 4.0 (95% CI 1.5-10.5) and 9.7 (95% CI 3.4-27.8), respectively. CONCLUSIONS Re-ETV seems to be as safe and effective as initial ETV. ETVSS adequately predicts the chance of successful re-ETV. The presence of prepontine arachnoid membranes and the use of EVD negatively influence the chance of success

Design of an Adaptive Cruise Control Model for Hybrid Systems Fault Diagnosis

Driver Assistance Systems like Adaptive Cruise Control (ACC) can help prevent accidents by reducing the workload on the driver. However, this can only be accomplished if the driver can rely on the system to perform safely even in the presence of faults. In this thesis we develop an Adaptive Cruise Control model that will be used to investigate Hybrid Systems Fault Diagnosis techniques. System Identification is performed upon an electric motor to obtain its transfer function. This electric motor belongs to a 1/10th scale RC car that is being used as part of a test bench for the Adaptive Cruise Control system. The identified model is then used to design a hybrid controller which will switch between a set of LQR controllers to create an example Adaptive Cruise Controller. The model of the controller is then used to generate fixed point code for implementation on the testbed and validation against the model controller. Finally a detailed hazard analysis of the resulting system is performed using Leveson's STPA.Master of Applied Science (MASc

Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group

Background: Sagopilone (ZK 219477), a lipophylic and synthetic analog of epothilone B, that crosses the blood-brain barrier has demonstrated preclinical activity in glioma models. Patients and methods: Patients with first recurrence/progression of glioblastoma were eligible for this early phase II and pharmacokinetic study exploring single-agent sagopilone (16 mg/m2 over 3 h every 21 days). Primary end point was a composite of either tumor response or being alive and progression free at 6 months. Overall survival, toxicity and safety and pharmacokinetics were secondary end points. Results: Thirty-eight (evaluable 37) patients were included. Treatment was well tolerated, and neuropathy occurred in 46% patients [mild (grade 1) : 32%]. No objective responses were seen. The progression-free survival (PFS) rate at 6 months was 6.7% [95% confidence interval (CI) 1.3-18.7], the median PFS was just over 6 weeks, and the median overall survival was 7.6 months (95% CI 5.3-12.3), with a 1-year survival rate of 31.6% (95% CI 17.7-46.4). Maximum plasma concentrations were reached at the end of the 3-h infusion, with rapid declines within 30 min after termination. Conclusions: No evidence of relevant clinical antitumor activity against recurrent glioblastoma could be detected. Sagopilone was well tolerated, and moderate-to-severe peripheral neuropathy was observed in despite prolonged administratio